Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Planken, S., Behenna, D.C., Nair, S.K., Johnson, T.O., Nagata, A., Almaden, C., Bailey, S., Ballard, T.E., Bernier, L., Cheng, H., Cho-Schultz, S., Dalvie, D., Deal, J.G., Dinh, D.M., Edwards, M.P., Ferre, R.A., Gajiwala, K.S., Hemkens, M., Kania, R.S., Kath, J.C., Matthews, J., Murray, B.W., Niessen, S., Orr, S.T., Pairish, M., Sach, N.W., Shen, H., Shi, M., Solowiej, J., Tran, K., Tseng, E., Vicini, P., Wang, Y., Weinrich, S.L., Zhou, R., Zientek, M., Liu, L., Luo, Y., Xin, S., Zhang, C., Lafontaine, J.
J. Med. Chem.